,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2018', 'fs': 'Feb 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtMUAQ'}, 'Id': 'a0P2P000006dvtMUAQ', 'Event_Date__c': '2018-02-05', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2018', 'Status_History__c': 'a132P000000ArOwQAK'}, 'change': None}]",Feb 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2018', 'fs': 'Jun 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtNUAQ'}, 'Id': 'a0P2P000006dvtNUAQ', 'Event_Date__c': '2018-06-13', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Jun 2018', 'Status_History__c': 'a132P000000ArTrQAK'}, 'change': None}, {'Summary': {'s': 'PTAC recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of indolent non-Hodgkins lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen be listed with a low priority.       PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the need for obinutuzumab for non-Hodgkin&#39;s lymphoma and the potential impact of increasing infusion requirements due to maintenance therapy.', 'fs': 'PTAC recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of indolent non-Hodgkins lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen be listed with a low priority.       PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the need for obinutuzumab for non-Hodgkin&#39;s lymphoma and the potential impact of increasing infusion requirements due to maintenance therapy.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Low', 'fs': 'Low', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtOUAQ'}, 'Id': 'a0P2P000006dvtOUAQ', 'Event_Date__c': '2018-08-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 August 2018.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Low', 'Summary__c': 'PTAC recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of indolent non-Hodgkins lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen be listed with a low priority.       PTAC recommended the application be referred to the Cancer Treatment Subcommittee of PTAC (CaTSoP) for advice regarding the need for obinutuzumab for non-Hodgkin&#39;s lymphoma and the potential impact of increasing infusion requirements due to maintenance therapy.', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVAQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'fs': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had considered the application for indolent NHL and recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation including that PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had also requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in October 2019 CaTSoP had recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee observed that CaTSoP had not considered any new evidence to that considered by PTAC in August 2018. However, the Committee noted and acknowledged CaTSoP’s advice, particularly that detailed in paragraph 8.22 and 8.23, regarding the administration requirements of obinutuzumab, the need of another agent for NHL, and the relevance of the clinical trial evidence from the GADOLIN trial to New Zealand patients.</p>', 'fs': '<p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had considered the application for indolent NHL and recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation including that PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had also requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in October 2019 CaTSoP had recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee observed that CaTSoP had not considered any new evidence to that considered by PTAC in August 2018. However, the Committee noted and acknowledged CaTSoP’s advice, particularly that detailed in paragraph 8.22 and 8.23, regarding the administration requirements of obinutuzumab, the need of another agent for NHL, and the relevance of the clinical trial evidence from the GADOLIN trial to New Zealand patients.</p>', 'change': None}, 'Outcome': {'s': 'Medium', 'fs': 'Medium', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtQUAQ'}, 'Id': 'a0P2P000006dvtQUAQ', 'Event_Date__c': '2019-10-18', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 18 October 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Medium', 'Formatted_Date__c': 'Oct 2019', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee made this recommendation due to the unmet need of this small patient group, the highly relevant clinical trial evidence (to New Zealand patients) and the evidence for a difference in PFS, a clear difference in OS (despite immature data) and reasonable toxicity profile associated with obinutuzumab.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following new Special Authority criteria for obinutuzumab for the treatment of the above recommended patient group: </p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Special Authority for Subsidy</span><span style=""font-size: 9pt; color: black;""> - PCT only – Specialist</span></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Initial application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</span></p><p>\t<span style=""font-size: 9pt;"">All of the following: </span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an indolent low grade lymphoma; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient is refractory to any previous regimen containing rituximab; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has an ECOG performance status of 0-2; and</span></p><p><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has been previously treated with no more than four chemotherapy regimens; and</span></p><p><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</span></p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Renewal application (indolent, low grade lymphomas) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</span></p><p><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has no evidence of disease progression following obinutuzumab induction therapy; and</span></p><p><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</span></p><p><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Obinutuzumab to be discontinued at disease progression.</span></p><p><br></p><p style=""text-align: justify;""><span style=""font-size: 9pt;"">Note: &#39;Indolent, low-grade lymphomas&#39; includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia. Rituximab-refractory is defined as failure to respond to, or progression during, any previous rituximab-containing regimen (monotherapy or combined with chemotherapy), or progression within 6 months of the last rituximab dose, in the induction or maintenance treatment settings. Response to first-line systemic chemotherapy in combination with obinutuzumab needs to be assessed 2-4 weeks after the last treatment course. Maintenance therapy should commence at 8 weeks after completion of the first-line systemic treatment.</span></p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee recommended the following change to the Special Authority criteria for bendamustine in both initial and renewal (additional text in <b>bold</b>): </p><p style=""text-align: justify;""><i style=""color: black; font-size: 10pt;"">Bendamustine is to be administered as a monotherapy </i><b style=""color: black; font-size: 10pt;""><i>or in combination with obinutuzumab</i></b><i style=""color: black; font-size: 10pt;""> for a maximum of 6 cycles in rituximab refractory patients</i></p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL) be deferred. </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee decided that in order to consider this application sufficiently it would need to see mature PFS and safety data for this patient group from the GALLIUM trial (unlikely to be available for at least a few years), and considered OS data was unlikely to be forthcoming in this patient group.\xa0</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered the following applications from Roche Products (New Zealand) Ltd:</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, and</p><p><span style=""color: black; font-family: Symbol;"">·</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>obinutuzumab for the first-line induction and maintenance treatment of adult patients with follicular lymphoma (FL).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p>General discussion</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that treatment of indolent non-Hodgkin lymphoma (NHL), including follicular lymphoma (FL), in New Zealand consists of multiple treatment lines using rituximab in combination with chemotherapy (predominantly bendamustine-rituximab for first line therapy), with stem cell transplant in appropriate cases at later relapse. The Subcommittee noted that funding restrictions for rituximab or bendamustine retreatment require rituximab- or bendamustine-treatment free intervals of 12-months. The Subcommittee noted that approximately 14% of patients with NHL will experience rituximab-refractory disease or relapse within six months of rituximab treatment. </p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that rituximab maintenance therapy for FL is not currently funded in New Zealand, but that an application for rituximab maintenance therapy for CD20+ low-grade or follicular B-cell NHL received a medium priority recommendation from CaTSoP in April 2018. The Subcommittee considered that funded rituximab maintenance would not change the health need of patients who ultimately become rituximab-refractory.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that treatment of indolent non-Hodgkin lymphoma in the third line and later is challenging, especially for rapidly relapsing disease, that most patients with NHL eventually relapse, and that antibody treatments (eg rituximab) offer more benefit if used in combination with chemotherapy.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab, like rituximab, is an anti-CD20 monoclonal antibody but that obinutuzumab has a broader mechanism of action and uses a direct pathway to cause malignant cell death. </p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that obinutuzumab is Medsafe-approved for first-line treatment of patients with FL (in combination with chemotherapy followed by maintenance) and for patients with indolent NHL who did not respond to, or who progressed during/within 6 months of prior rituximab (in combination with bendamustine followed by maintenance).</p><p>Obinutuzumab for relapsed/refractory indolent NHL </p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for indolent NHL was reviewed by PTAC, which recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p><span style=""color: black;"">1.7.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the applicant’s patient number estimate (N = 36) was reasonable and the estimate by PHARMAC staff (N = 9, based on bendamustine use in rituximab-refractory patients) was too low, but that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have co-morbidities. The Subcommittee considered that the small group of patients with relapsed/refractory indolent NHL have an unmet health need and that uptake of obinutuzumab plus bendamustine could be low due to patient characteristics. </p><p><span style=""color: black;"">1.8.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab in combination with bendamustine for rituximab-refractory indolent NHL comes from the phase 3 GADOLIN trial; an open-label, randomised (1:1), multicentre trial that investigated the efficacy and safety of induction therapy with obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy, compared with bendamustine monotherapy induction therapy, in 413 patients with rituximab-refractory indolent NHL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/27345636"" target=""_blank"">(Sehn et al. Lancet Oncol. 2016;17:1081-93; Cheson et al. J Clin Oncol. 2018;36:2259-66).</a> </p><p><span style=""color: black;"">1.9.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that limitations of the GADOLIN trial design and patient group characteristics would have biased the results; specifically, different doses of bendamustine (120 mg as monotherapy; 90 mg with obinutuzumab), use of bendamustine monotherapy as a comparator and without maintenance (patients more likely to progress than with obinutuzumab plus bendamustine), imbalances in the proportion of patients refractory to prior rituximab monotherapy (18.6% in the obinutuzumab plus bendamustine group and 23.0% in the monotherapy group in the intention-to-treat population, and in 15.2% and 24.6%, respectively, of patients with FL), and broad definitions of rituximab-refractory (applying to prior rituximab monotherapy and rituximab-containing combination chemotherapy regimens). The Subcommittee considered that rituximab monotherapy is seldom used in New Zealand, as patients may respond to rituximab with chemotherapy. </p><p><span style=""color: black;"">1.10.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted the UK National Institute for Health and Care Excellence (NICE) technology appraisal of obinutuzumab plus bendamustine had reported limitations in estimates of overall survival (OS) which favoured the intervention <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29594951"" target=""_blank"">(Rafia et al. Pharmacoeconomics. 2018;36:1143-51)</a>.</p><p><span style=""color: black;"">1.11.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the median progression-free survival (PFS) in the GADOLIN trial was 25.8 months with obinutuzumab plus bendamustine compared to 14.1 months with bendamustine monotherapy (HR 0.57; 95% CI 0.44 to 0.73; P&lt;0.001). The Subcommittee noted that median OS was not reached for either group, where the Kaplan Meir survival differences were statistically significant (HR 0.67; 95% CI 0.47-0.96; P=0.0269) and considered that a reasonable number of survival events had occurred. The Subcommittee noted that the PFS and OS results were consistent in the FL patient subgroups <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29584548"" target=""_blank"">(Cheson et al. J Clin Oncol. 2018;36:2259-66)</a>.</p><p><span style=""color: black;"">1.12.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that obinutuzumab had a reasonable safety profile, that adverse events (AEs) were similar between the treatment groups, and that the higher proportion of treatment withdrawals due to AEs with bendamustine monotherapy may be due to poor tolerance of the larger bendamustine dose in this group.</p><p><span style=""color: black;"">1.13.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that GADOLIN demonstrated a PFS benefit and an apparent OS effect, despite the published data not being fully mature and the limitations of the trial. </p><p><span style=""color: black;"">1.14.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the clinical trial evidence from the GADOLIN trial was highly relevant to New Zealand patients with indolent NHL, because the trial control arm used bendamustine monotherapy as would be the case in New Zealand for rituximab-refractory patients where a rituximab treatment-free interval of 12 months or more is required for renewal of rituximab on relapse. </p><p><span style=""color: black;"">1.15.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the infusion resource required to administer obinutuzumab maintenance every 2 months for 2 years or until disease progression was small, that a small number of patients would receive this treatment, and that obinutuzumab maintenance would require similar infusion resources to maintenance rituximab (if funded), however, obinutuzumab may be more challenging to administer than rituximab. The Subcommittee considered that uptake of this regimen might be quite low. </p><p>Obinutuzumab for first-line treatment of FL</p><p><span style=""color: black;"">1.16.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a> the application for FL was reviewed by PTAC, which recommended the application be deferred pending further data, and that PTAC considered it should be funded only if cost-neutral to rituximab maintenance. The Subcommittee noted the reasons PTAC had given for its recommendation were what PTAC considered evidence of improved PFS but no evidence of quality of life benefit and no clear evidence of OS benefit with obinutuzumab compared with rituximab. The Subcommittee also noted that PTAC had requested advice from CaTSoP regarding the long-term safety data of obinutuzumab and the likely efficacy of retreatment with obinutuzumab or rituximab.</p><p><span style=""color: black;"">1.17.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the patient number estimates by the applicant (N = 119) and PHARMAC staff (N = 88) were reasonable estimates of the number of newly diagnosed patients with FL, although they could be slightly overestimated.</p><p><span style=""color: black;"">1.18.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the primary evidence for the efficacy of obinutuzumab induction and maintenance therapy for the first-line treatment of FL derives from the GALLIUM trial; an open-label, phase 3, randomised (1:1) trial that investigated the efficacy and safety of obinutuzumab plus chemotherapy induction therapy compared with rituximab plus chemotherapy followed by maintenance with the same antibody in 1202 patients with previously untreated FL <a href=""https://www.ncbi.nlm.nih.gov/pubmed/28976863"" target=""_blank"">(Marcus et al. N Engl J Med. 2017;377:1331-44</a>; <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.19.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the GALLIUM trial was of good quality, where it included patients with up to grade 3a disease, used the GELF tumour burden criteria for treatment eligibility, had a standard rituximab treatment schedule, and had a good balance of patients between treatment groups. The Subcommittee noted that three chemotherapy regimens were allowed: bendamustine (used in 57.1% of patients), CHOP (33.1%) and CVP (9.8%).</p><p><span style=""color: black;"">1.20.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that after a median follow-up of 41 months, the 3-year investigator-assessed PFS rate in the GALLIUM trial was 82% in the obinutuzumab group compared with 75% in the rituximab group (HR 0.68; 95% CI 0.54 to 0.87; P=0.0016), and that results of PFS as assessed by independent review committee were similar. Members considered that the PFS results by chemotherapy regimen were consistent. The Subcommittee noted that the 3-year OS rate was 94% in the obinutuzumab group compared with 92% in the rituximab group (HR 0.82; 95% CI 0.54 to 1.22; P=0.32) <a href=""https://www.ncbi.nlm.nih.gov/pubmed/29856692"" target=""_blank"">(Hiddemann et al. J Clin Oncol. 2018;36:2395-404).</a> </p><p><span style=""color: black;"">1.21.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that secondary malignancy occurred in 5% of patients receiving bendamustine, more infections were reported in patients receiving bendamustine (20-26%) than other regimens (12-20%), and higher rates of grade 3-5 cytopenias were reported in patients receiving CHOP than with other regimens. The Subcommittee considered these safety signals were small, but that longer-term data is needed to evaluate their clinical significance. </p><p><span style=""color: black;"">1.22.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that in patients older than 70 years that a higher proportion of fatal events occurred prior to starting new anticancer therapy with bendamustine (13%) compared with CHOP (2%) or CVP (4%), and considered this was a concern due to patients likely being older at the time of their diagnosis with FL.</p><p><span style=""color: black;"">1.23.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee considered that the difference in PFS between groups was small and that the GALLIUM trial data was too immature to conclude whether obinutuzumab would be preferred over rituximab for induction and maintenance treatment for FL. The Subcommittee requested that it see mature efficacy and safety data, once available, although it considered these data unlikely to be available for at least a few years. The Subcommittee considered that OS data was unlikely to be produced as it is challenging to obtain this in FL, due to confounding from crossovers with subsequent multiple lines of therapy.</p><p><span style=""color: black;"">1.24.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that there is no available data for retreatment using either obinutuzumab or rituximab after obinutuzumab in the first-line setting, and considered that the efficacy and safety of retreatment with obinutuzumab or rituximab is currently unknown. The Subcommittee considered that long-term safety and efficacy data are lacking in FL and there is a small signal for increased infections and secondary malignancy that requires additional follow up to determine if this is a concern.</p>', 'PTAC_Comments__c': '<p>1.1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had considered the application for indolent NHL and recommended funding with a low priority, and noted the reasons PTAC had given for its recommendation including that PTAC considered evidence of improved PFS, uncertain evidence of an OS benefit, and no significant difference in safety or HRQoL. </p><p>1.1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in August 2018 PTAC had also requested advice from CaTSoP regarding the need for another agent in NHL and the potential impact of increasing infusion requirements due to maintenance therapy.</p><p>1.1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that in October 2019 CaTSoP had recommended that obinutuzumab in combination with bendamustine followed by obinutuzumab monotherapy for the treatment of patients with indolent non-Hodgkin lymphoma (NHL) who relapsed after, or are refractory to, a rituximab-containing regimen, be funded with a medium priority.</p><p>1.1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee observed that CaTSoP had not considered any new evidence to that considered by PTAC in August 2018. However, the Committee noted and acknowledged CaTSoP’s advice, particularly that detailed in paragraph 8.22 and 8.23, regarding the administration requirements of obinutuzumab, the need of another agent for NHL, and the relevance of the clinical trial evidence from the GADOLIN trial to New Zealand patients.</p>', 'Status_History__c': 'a132P000000BTMZQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtRUAQ'}, 'Id': 'a0P2P000006dvtRUAQ', 'Event_Date__c': '2020-02-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BTLwQAO'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>4.2.\tThe Subcommittee noted its previous recommendation to fund obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma (NHL) which has relapsed after, or is refractory to, a rituximab-containing regimen with a medium priority (October 2018). The Subcommittee, during its review recommended altering the Special Authority criteria to better align with the available evidence supporting the use of obinutuzumab in this patient population.</p><p>4.3.\tThe Subcommittee noted that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have comorbidities. The Subcommittee noted that in New Zealand many patients with indolent NHL receive bendamustine in combination with rituximab as first line chemotherapy. The Subcommittee noted that the GADOLIN trial did not report how many patients had received bendamustine previously (Cheson et al. J Clin Oncol. 2018;36:2259-66).\xa0</p><p>4.4.\tThe Subcommittee noted that most some patients would be re-exposed to bendamustine in combination with rituximab if a protracted initial response was achieved. The Subcommittee noted that some patients with relapsed low grade lymphomas may receive salvage chemotherapy and autologous transplant. The Subcommittee noted that if relapse was recent, retreatment with rituximab would not be allowed under access criteria and other patients might try alkylating agents with or without rituximab (eg. rituximab in combination with cyclophosphamide, vincristine and prednisolone). The Subcommittee considered that combination chemotherapy such as R-CHOP chemotherapy may be used in patients with a short response to first line treatment with bendamustine in combination with rituximab.. The Subcommittee considered that the primary benefit of funding obinutuzumab would be in a patient group refractory to, or who relapse early after treatment with a rituximab containing treatment regimen.</p><p>4.5.\tThe Subcommittee noted that patients with disease that is refractory to treatment or who progress early can be defined very specifically by Lugano criteria (van Heertum et al. Drug Des Devel Ther. 017;11:1719-28).In clinical practice however these specific criteria are not stringently applied outside of research studies, or as part of eligibility criteria specific to transplantation. The Subcommittee considered that the availability of obinutuzumab may result in additional testing to detect radiological relapse.</p><p>4.6.\tThe Subcommittee noted that patient uptake is difficult to estimate. However, the Subcommittee considered that up to 20% of patients with follicular lymphoma would progress within 6 months of treatment commencement. Additional drivers may include: the potential low tolerability of obinutuzumab; that bendamustine is not the only initial treatment for patients with indolent NHL and may end up being intolerable for some patients; that some will have lymphoma transformation (10-20%) and not want to use bendamustine in combination with obinutuzumab; and that some patients would not want to be re-exposed to bendamustine. The Subcommittee considered that the percentage of patients with indolent NHL who would end up receiving obinutuzumab, if funded, would be no more than 10%. The Subcommittee estimated this based on an uptake rate of approximately 50% and the evidence indicating that 14% of (up taking) patients would be refractory to rituximab (Tarella C et al. PLoS One. 2014;9:e106745).\xa0</p><p>4.7.\tThe Subcommittee noted that the GADOLIN trial did not include patients with mantle cell lymphoma and that only one patient with Waldenström macroglobulinaemia was included in the study, and noted that treatments such as ibrutinib may be appropriate for these patients. The Subcommittee considered that the criteria for access should therefore be limited to patients with follicular and marginal zone lymphoma. The Subcommittee considered that this criterion would limit access to approximately 75% of patients with indolent low-grade lymphomas.</p><p>4.8.\tThe Subcommittee noted that the GADOLIN trial included patients who had refractory disease or had relapsed within 6 months of rituximab with/without chemotherapy. About half of the patients had refractory disease or had relapsed after induction rituximab/chemotherapy, the other half progressed in the 6 months after rituximab maintenance. The Subcommittee considered that it would be reasonable to limit access to only those patients who have relapsed within 6 months of receipt of rituximab to align with the intent of the patient population and the unmet need.</p><p>4.9.\tThe Subcommittee therefore considered that it would be appropriate to amend the proposed Special Authority criteria for obinutuzumab as follows:</p><p>Special Authority for Subsidy - PCT only – Specialist</p><p>Initial application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1.\tEither:</p><p>1.1.\tPatient has follicular lymphoma; or</p><p>1.2.\tPatient has marginal zone lymphoma; and</p><p>2.\tPatient is refractory to any previous regimen containing rituximab within six months after treatment with rituximab; and</p><p>3.\tPatient has an ECOG performance status of 0-2; and</p><p>4.\tPatient has been previously treated with no more than four chemotherapy regimens; and</p><p>5.\tObinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</p><p><br></p><p>Renewal application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</p><p>1.\tPatient has no evidence of disease progression following obinutuzumab induction therapy; and</p><p>2.\tObinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</p><p>3.\tObinutuzumab to be discontinued at disease progression.</p><p><br></p>', 'fs': '<p>4.2.\tThe Subcommittee noted its previous recommendation to fund obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma (NHL) which has relapsed after, or is refractory to, a rituximab-containing regimen with a medium priority (October 2018). The Subcommittee, during its review recommended altering the Special Authority criteria to better align with the available evidence supporting the use of obinutuzumab in this patient population.</p><p>4.3.\tThe Subcommittee noted that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have comorbidities. The Subcommittee noted that in New Zealand many patients with indolent NHL receive bendamustine in combination with rituximab as first line chemotherapy. The Subcommittee noted that the GADOLIN trial did not report how many patients had received bendamustine previously (Cheson et al. J Clin Oncol. 2018;36:2259-66).\xa0</p><p>4.4.\tThe Subcommittee noted that most some patients would be re-exposed to bendamustine in combination with rituximab if a protracted initial response was achieved. The Subcommittee noted that some patients with relapsed low grade lymphomas may receive salvage chemotherapy and autologous transplant. The Subcommittee noted that if relapse was recent, retreatment with rituximab would not be allowed under access criteria and other patients might try alkylating agents with or without rituximab (eg. rituximab in combination with cyclophosphamide, vincristine and prednisolone). The Subcommittee considered that combination chemotherapy such as R-CHOP chemotherapy may be used in patients with a short response to first line treatment with bendamustine in combination with rituximab.. The Subcommittee considered that the primary benefit of funding obinutuzumab would be in a patient group refractory to, or who relapse early after treatment with a rituximab containing treatment regimen.</p><p>4.5.\tThe Subcommittee noted that patients with disease that is refractory to treatment or who progress early can be defined very specifically by Lugano criteria (van Heertum et al. Drug Des Devel Ther. 017;11:1719-28).In clinical practice however these specific criteria are not stringently applied outside of research studies, or as part of eligibility criteria specific to transplantation. The Subcommittee considered that the availability of obinutuzumab may result in additional testing to detect radiological relapse.</p><p>4.6.\tThe Subcommittee noted that patient uptake is difficult to estimate. However, the Subcommittee considered that up to 20% of patients with follicular lymphoma would progress within 6 months of treatment commencement. Additional drivers may include: the potential low tolerability of obinutuzumab; that bendamustine is not the only initial treatment for patients with indolent NHL and may end up being intolerable for some patients; that some will have lymphoma transformation (10-20%) and not want to use bendamustine in combination with obinutuzumab; and that some patients would not want to be re-exposed to bendamustine. The Subcommittee considered that the percentage of patients with indolent NHL who would end up receiving obinutuzumab, if funded, would be no more than 10%. The Subcommittee estimated this based on an uptake rate of approximately 50% and the evidence indicating that 14% of (up taking) patients would be refractory to rituximab (Tarella C et al. PLoS One. 2014;9:e106745).\xa0</p><p>4.7.\tThe Subcommittee noted that the GADOLIN trial did not include patients with mantle cell lymphoma and that only one patient with Waldenström macroglobulinaemia was included in the study, and noted that treatments such as ibrutinib may be appropriate for these patients. The Subcommittee considered that the criteria for access should therefore be limited to patients with follicular and marginal zone lymphoma. The Subcommittee considered that this criterion would limit access to approximately 75% of patients with indolent low-grade lymphomas.</p><p>4.8.\tThe Subcommittee noted that the GADOLIN trial included patients who had refractory disease or had relapsed within 6 months of rituximab with/without chemotherapy. About half of the patients had refractory disease or had relapsed after induction rituximab/chemotherapy, the other half progressed in the 6 months after rituximab maintenance. The Subcommittee considered that it would be reasonable to limit access to only those patients who have relapsed within 6 months of receipt of rituximab to align with the intent of the patient population and the unmet need.</p><p>4.9.\tThe Subcommittee therefore considered that it would be appropriate to amend the proposed Special Authority criteria for obinutuzumab as follows:</p><p>Special Authority for Subsidy - PCT only – Specialist</p><p>Initial application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1.\tEither:</p><p>1.1.\tPatient has follicular lymphoma; or</p><p>1.2.\tPatient has marginal zone lymphoma; and</p><p>2.\tPatient is refractory to any previous regimen containing rituximab within six months after treatment with rituximab; and</p><p>3.\tPatient has an ECOG performance status of 0-2; and</p><p>4.\tPatient has been previously treated with no more than four chemotherapy regimens; and</p><p>5.\tObinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</p><p><br></p><p>Renewal application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</p><p>1.\tPatient has no evidence of disease progression following obinutuzumab induction therapy; and</p><p>2.\tObinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</p><p>3.\tObinutuzumab to be discontinued at disease progression.</p><p><br></p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted concerns raised by Pharmac staff when creating the model for obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted concerns raised by Pharmac staff when creating the model for obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen.</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtUUAQ'}, 'Id': 'a0P2P000006dvtUUAQ', 'Event_Date__c': '2021-08-03', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Monday 12 April 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2021', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0</span>The Subcommittee noted concerns raised by Pharmac staff when creating the model for obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma which has relapsed after, or is refractory to, a rituximab-containing regimen.</p>', 'Published_Discussion__c': '<p>4.2.\tThe Subcommittee noted its previous recommendation to fund obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance monotherapy for the treatment of indolent non-Hodgkin lymphoma (NHL) which has relapsed after, or is refractory to, a rituximab-containing regimen with a medium priority (October 2018). The Subcommittee, during its review recommended altering the Special Authority criteria to better align with the available evidence supporting the use of obinutuzumab in this patient population.</p><p>4.3.\tThe Subcommittee noted that bendamustine may be contraindicated in patients who are heavily pre-treated, of advanced age, or have comorbidities. The Subcommittee noted that in New Zealand many patients with indolent NHL receive bendamustine in combination with rituximab as first line chemotherapy. The Subcommittee noted that the GADOLIN trial did not report how many patients had received bendamustine previously (Cheson et al. J Clin Oncol. 2018;36:2259-66).\xa0</p><p>4.4.\tThe Subcommittee noted that most some patients would be re-exposed to bendamustine in combination with rituximab if a protracted initial response was achieved. The Subcommittee noted that some patients with relapsed low grade lymphomas may receive salvage chemotherapy and autologous transplant. The Subcommittee noted that if relapse was recent, retreatment with rituximab would not be allowed under access criteria and other patients might try alkylating agents with or without rituximab (eg. rituximab in combination with cyclophosphamide, vincristine and prednisolone). The Subcommittee considered that combination chemotherapy such as R-CHOP chemotherapy may be used in patients with a short response to first line treatment with bendamustine in combination with rituximab.. The Subcommittee considered that the primary benefit of funding obinutuzumab would be in a patient group refractory to, or who relapse early after treatment with a rituximab containing treatment regimen.</p><p>4.5.\tThe Subcommittee noted that patients with disease that is refractory to treatment or who progress early can be defined very specifically by Lugano criteria (van Heertum et al. Drug Des Devel Ther. 017;11:1719-28).In clinical practice however these specific criteria are not stringently applied outside of research studies, or as part of eligibility criteria specific to transplantation. The Subcommittee considered that the availability of obinutuzumab may result in additional testing to detect radiological relapse.</p><p>4.6.\tThe Subcommittee noted that patient uptake is difficult to estimate. However, the Subcommittee considered that up to 20% of patients with follicular lymphoma would progress within 6 months of treatment commencement. Additional drivers may include: the potential low tolerability of obinutuzumab; that bendamustine is not the only initial treatment for patients with indolent NHL and may end up being intolerable for some patients; that some will have lymphoma transformation (10-20%) and not want to use bendamustine in combination with obinutuzumab; and that some patients would not want to be re-exposed to bendamustine. The Subcommittee considered that the percentage of patients with indolent NHL who would end up receiving obinutuzumab, if funded, would be no more than 10%. The Subcommittee estimated this based on an uptake rate of approximately 50% and the evidence indicating that 14% of (up taking) patients would be refractory to rituximab (Tarella C et al. PLoS One. 2014;9:e106745).\xa0</p><p>4.7.\tThe Subcommittee noted that the GADOLIN trial did not include patients with mantle cell lymphoma and that only one patient with Waldenström macroglobulinaemia was included in the study, and noted that treatments such as ibrutinib may be appropriate for these patients. The Subcommittee considered that the criteria for access should therefore be limited to patients with follicular and marginal zone lymphoma. The Subcommittee considered that this criterion would limit access to approximately 75% of patients with indolent low-grade lymphomas.</p><p>4.8.\tThe Subcommittee noted that the GADOLIN trial included patients who had refractory disease or had relapsed within 6 months of rituximab with/without chemotherapy. About half of the patients had refractory disease or had relapsed after induction rituximab/chemotherapy, the other half progressed in the 6 months after rituximab maintenance. The Subcommittee considered that it would be reasonable to limit access to only those patients who have relapsed within 6 months of receipt of rituximab to align with the intent of the patient population and the unmet need.</p><p>4.9.\tThe Subcommittee therefore considered that it would be appropriate to amend the proposed Special Authority criteria for obinutuzumab as follows:</p><p>Special Authority for Subsidy - PCT only – Specialist</p><p>Initial application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:</p><p>All of the following:</p><p>1.\tEither:</p><p>1.1.\tPatient has follicular lymphoma; or</p><p>1.2.\tPatient has marginal zone lymphoma; and</p><p>2.\tPatient is refractory to any previous regimen containing rituximab within six months after treatment with rituximab; and</p><p>3.\tPatient has an ECOG performance status of 0-2; and</p><p>4.\tPatient has been previously treated with no more than four chemotherapy regimens; and</p><p>5.\tObinutuzumab to be administered at a maximum dose of 1000 mg in combination with bendamustine at a maximum dose of 90 mg/m2 for a maximum of 6 cycles; and</p><p><br></p><p>Renewal application (follicular / marginal zone lymphoma) - only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:</p><p>1.\tPatient has no evidence of disease progression following obinutuzumab induction therapy; and</p><p>2.\tObinutuzumab to be administered at a maximum of 1000 mg every 2 months for a maximum of 2 years; and</p><p>3.\tObinutuzumab to be discontinued at disease progression.</p><p><br></p>', 'Status_History__c': 'a132P000000D4JrQAK'}, 'change': None}]",Jun 2018,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2018', 'fs': 'Aug 2018', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtPUAQ'}, 'Id': 'a0P2P000006dvtPUAQ', 'Event_Date__c': '2018-08-10', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Aug 2018', 'Status_History__c': 'a132P000000ArVXQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2020', 'fs': 'May 2020', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtSUAQ'}, 'Id': 'a0P2P000006dvtSUAQ', 'Event_Date__c': '2020-05-15', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2020', 'Status_History__c': 'a132P000000BlGgQAK'}, 'change': None}]",Aug 2018,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2020', 'fs': 'Sep 2020', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtTUAQ'}, 'Id': 'a0P2P000006dvtTUAQ', 'Event_Date__c': '2020-09-28', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2020', 'Status_History__c': 'a132P000000CKAZQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2021', 'fs': 'Dec 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtVUAQ'}, 'Id': 'a0P2P000006dvtVUAQ', 'Event_Date__c': '2021-12-14', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2021', 'Status_History__c': 'a132P000000DPxDQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2022', 'fs': 'Jul 2022', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtXUAQ'}, 'Id': 'a0P2P000006dvtXUAQ', 'Event_Date__c': '2022-07-26', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jul 2022', 'Status_History__c': 'a132P000000Dw5TQAS'}, 'change': None}]",Sep 2020,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/"" target=""_blank"">Consultation for breast and blood cancer</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/"" target=""_blank"">Consultation for breast and blood cancer</a></p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2022', 'fs': 'May 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtWUAQ'}, 'Id': 'a0P2P000006dvtWUAQ', 'Event_Date__c': '2022-05-19', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Summary__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2022-05-19-proposals-to-fund-treatments-for-people-with-breast-and-blood-cancers/"" target=""_blank"">Consultation for breast and blood cancer</a></p>', 'Formatted_Date__c': 'May 2022', 'Status_History__c': 'a132P000000DlwCQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtYUAQ'}, 'Id': 'a0P2P000006dvtYUAQ', 'Event_Date__c': '2022-09-07', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E2WaQAK'}, 'change': None}]",May 2022,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtZUAQ'}, 'Id': 'a0P2P000006dvtZUAQ', 'Event_Date__c': '2022-09-07', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E2WfQAK'}, 'change': None}]",Sep 2022,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-08-18-obinutuzumab/', 'fs': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-08-18-obinutuzumab/', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2022', 'fs': 'Sep 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been .', 'fs': 'The funding application has been .', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006dvtaUAA'}, 'Id': 'a0P2P000006dvtaUAA', 'Event_Date__c': '2022-09-07', 'Event_Description__c': 'The funding application has been .', 'Stage__c': 'Decision', 'Summary__c': 'https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-08-18-obinutuzumab/', 'Formatted_Date__c': 'Sep 2022', 'Status_History__c': 'a132P000000E2WkQAK'}, 'change': None}]",Sep 2022,False,True
